LH Levels by Age: What Your Number Actually Means at Every Decade of Life

What Is LH and Why Does It Matter for Women Specifically?

Luteinizing hormone is a glycoprotein released in pulses from the anterior pituitary under the direction of hypothalamic GnRH. In women, it controls two things that have no male equivalent: the mid-cycle surge that triggers ovulation, and the luteinization of the ruptured follicle into the corpus luteum that produces progesterone. Textbook descriptions often present LH as a shared reproductive hormone, but its physiological meaning in women is cycle-dependent in a way that has no parallel in male physiology.

LH also stimulates ovarian theca cells to produce androgens, which are then aromatized to estrogen in granulosa cells. This is why disordered LH pulsatility, as seen in PCOS, drives androgen excess and the hormonal acne, hirsutism, and anovulation that follow.

The Hypothalamic-Pituitary-Ovarian Axis in Plain Language

The HPO axis works like a thermostat with two settings. Before ovulation, rising estrogen eventually flips from negative to positive feedback, triggering the LH surge. After ovulation, progesterone and estrogen together suppress GnRH pulsatility and hold LH low. When ovarian estrogen production falls permanently, as in menopause, the thermostat loses its sensor and LH climbs without restraint.

Understanding this loop is why a single LH number, reported without cycle day or hormonal context, is close to useless.

What LH Does NOT Tell You

LH does not confirm pregnancy (hCG does). It does not measure ovarian reserve (that is AMH and antral follicle count). It does not diagnose endometriosis or fibroids directly. Clinicians sometimes over-order it; the result only becomes meaningful when you also know where you are in your cycle, your FSH, estradiol, and your clinical picture.

LH Reference Ranges: The Numbers by Cycle Phase

According to the Mayo Clinic Laboratories reference intervals for serum LH in premenopausal women, the accepted ranges are:

| Cycle Phase | LH Range (IU/L) | |---|---| | Follicular (day 2-5) | 1.9 to 12.5 | | Mid-cycle surge peak | 21.9 to 56.6 | | Luteal phase | 0.5 to 16.9 | | Postmenopausal | 14.2 to 52.3 |

These are population-derived ranges. An LH of 14 IU/L means ovulation just ended if you are on cycle day 16, probable ovarian insufficiency if you are 35 with irregular cycles, and entirely expected if you are 58.

The mid-cycle surge deserves special attention. LH rises from baseline to peak in as little as 12 to 24 hours, and ovulation occurs 34 to 36 hours after surge onset. Urine LH strips detect this surge roughly 12-24 hours before serum, which is why they are used for timed intercourse.

LH in Your 20s: Establishing a Baseline

In the early reproductive years, the HPO axis is typically well-regulated. Follicular-phase LH should sit between 1.9 and 12.5 IU/L, with clean mid-cycle surges and a functional luteal phase. A 2018 analysis published in Fertility and Sterility found that median follicular-phase LH in healthy, regularly cycling women aged 18-30 was approximately 5.0 IU/L, with the inter-individual range wide even within this group.

When LH Is High in Your 20s

An elevated LH on cycle day 2-5, particularly when the LH:FSH ratio exceeds 2:1, is one of the diagnostic clues for PCOS. The Rotterdam criteria, the most widely used PCOS diagnostic framework, require two of three features: irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. LH elevation is not in the formal criteria but it supports the picture.

An LH:FSH ratio above 2:1 on a fasting cycle day 2-5 draw, combined with a total testosterone above the lab's female upper limit and clinical signs, should prompt a full PCOS workup.

When LH Is Low in Your 20s

A low or undetectable LH in a woman with absent periods in her 20s points toward hypothalamic amenorrhea. Energy deficiency from undereating, high-intensity training, or stress suppresses GnRH pulsatility, which collapses LH. A case series in the Journal of Clinical Endocrinology and Metabolism found that women with functional hypothalamic amenorrhea had mean LH pulse frequency reduced by approximately 50% compared with eumenorrheic controls. These women also have low estradiol and low bone density risk, which makes restoration of the energy balance and return of menses a clinical priority.

LH in Your 30s: Fertility Window and Early Warning Signs

The 30s are when women most often actively manage fertility and when early signs of ovarian aging can appear. Follicular-phase LH remains in the same 1.9-12.5 IU/L range through most of this decade, but FSH begins its gradual rise as ovarian reserve declines.

Premature Ovarian Insufficiency: The LH Signal Before Age 40

Premature ovarian insufficiency (POI) affects approximately 1 in 100 women before age 40. The diagnostic criterion, per the European Society of Human Reproduction and Embryology, is an FSH above 25 IU/L on two occasions at least four weeks apart, combined with oligo/amenorrhea for at least four months. LH rises in parallel. If your LH is persistently above 20-25 IU/L in your mid-to-late 30s with cycle irregularity, POI must be ruled out before assuming perimenopause.

This distinction matters enormously. Women with POI are at elevated fracture risk, cardiovascular risk, and cognitive risk from estrogen deficiency that is earlier and more prolonged than natural menopause. ACOG recommends hormone therapy for women with POI through at least the average age of natural menopause (around 51), unless contraindicated.

LH During IVF Stimulation in Your 30s

During ovarian stimulation, exogenous gonadotropins suppress the HPO axis. A premature LH surge before oocyte retrieval can ruin a cycle. GnRH antagonist protocols (cetrorelix, ganirelix) block LH surges effectively and are now preferred in most younger patients for this reason.

LH in Your 40s: Perimenopause Begins

The perimenopausal transition typically starts in the mid-to-late 40s, though it can begin as early as 40. FSH rises first, often before cycle irregularity is noticeable. LH follows. The transition is characterized by wide hormonal swings, not a smooth linear rise.

The SWAN (Study of Women's Health Across the Nation) longitudinal cohort documented that FSH and LH begin rising measurably approximately two to three years before the final menstrual period. LH variability is extreme during perimenopause. A single measurement can land anywhere in its reference range, making serial measurements or clinical staging (using the STRAW+10 criteria) more reliable than a snapshot LH.

Why a Single LH Cannot Diagnose Perimenopause

This is one of the most common misunderstandings in women's health. The Menopause Society (formerly NAMS) states explicitly that FSH and LH testing is unreliable for confirming perimenopause because of high cycle-to-cycle variability. Perimenopause is a clinical diagnosis based on symptom history and menstrual pattern, not a lab value.

If you are 46 with hot flashes and irregular cycles, you are likely perimenopausal regardless of whether your LH is 8 or 28 on any given day.

LH and Hormonal Contraception in Your 40s

Combined hormonal contraceptives suppress LH and FSH to near-zero, preventing the mid-cycle surge and thereby preventing ovulation. This is the primary mechanism of action. A Cochrane review confirmed that LH surge suppression is the dominant contraceptive mechanism of combined oral contraceptives. If you are on the pill and order a hormone panel, your LH will be artificially suppressed. The test should be done off hormonal contraception for at least two to three full cycles to be interpretable.

LH in Your 50s and Beyond: Postmenopause

After the final menstrual period and one year without cycles, postmenopause begins. Ovarian estrogen production has fallen to very low levels. The negative feedback loop is broken. LH rises to, and stays at, levels that would indicate an LH surge in a younger woman.

The established postmenopausal reference range of 14.2 to 52.3 IU/L reflects this state. An LH of 35 IU/L in a 58-year-old woman is normal and expected. The same value in a 32-year-old with irregular cycles requires urgent evaluation.

Does LH Have Any Clinical Use After Menopause?

Rarely. The main situations where LH still matters after menopause:

1. Distinguishing primary ovarian failure (high LH/FSH) from secondary hypogonadism (low or inappropriately normal LH/FSH), which could indicate a pituitary tumor or infiltrative disease.
2. Monitoring women on GnRH agonist therapy for conditions like hormone-sensitive cancers or endometriosis, where suppression of LH to near-zero is the therapeutic target.
3. Unexplained new symptoms in a postmenopausal woman on hormone therapy, where the LH level is one piece of the diagnostic picture.

Hormone Therapy and LH After Menopause

Systemic estrogen therapy modestly suppresses LH in postmenopausal women via restored negative feedback, but levels rarely return to premenopausal follicular-phase values. A randomized trial published in Menopause found that standard-dose oral estradiol (1-2 mg/day) reduced mean LH by approximately 40% from pretreatment postmenopausal levels. Transdermal estradiol produces a similar but sometimes smaller suppression depending on dose and application.

The LH:FSH Ratio: A Framework for Interpretation

The ratio of LH to FSH on a fasting cycle day 2-5 draw (or any morning draw in a postmenopausal or amenorrheic woman) is more informative than either value alone. Here is how to read it:

| LH:FSH Ratio | Clinical Signal | |---|---| | <1:1 (FSH dominates) | Early follicular phase, POI/menopause, or hypothalamic suppression | | Approximately 1:1 | Normal follicular phase baseline | | >2:1 (LH dominates) | Suggestive of PCOS in reproductive-age woman | | >3:1 | Strongly suggestive of PCOS or exogenous androgen/LH disruption | | Both very low | Hypothalamic amenorrhea, hypopituitarism, or suppressive medications | | Both very high | Postmenopausal state or primary ovarian insufficiency |

This framework does not replace clinical judgment, but it gives you a structured way to interpret two numbers that are often reported side by side with no interpretive guidance.

LH and Female-Specific Conditions

PCOS

Elevated LH with a high LH:FSH ratio is a classic PCOS feature, though it is present in only about 40 to 60% of women with PCOS, not all. The elevated LH drives excess theca-cell androgen production, contributing to androgen-related symptoms. Weight loss of 5-10% of body weight in women with PCOS can reduce LH pulse amplitude and restore more normal cycle dynamics.

Hypothalamic Amenorrhea

Low LH (often <2 IU/L) with low FSH, low estradiol, and no cycles. The fix is addressing the underlying energy deficit, not medication in most cases. Pulsatile GnRH (kisspeptin research is ongoing) or exogenous gonadotropins can be used for ovulation induction when fertility is the goal, but they do not treat the root cause.

Premature Ovarian Insufficiency

Persistently elevated LH and FSH before age 40. Approximately 90% of women with POI have no identifiable cause; autoimmune oophoritis, fragile X premutation, and Turner mosaicism are the detectable ones. The clinical consequence is hypoestrogenism at an age when estrogen is protective for bone, cardiovascular tissue, and the brain.

Endometriosis

LH is not a diagnostic marker for endometriosis. Endometriosis is diagnosed surgically. However, women with endometriosis who are on GnRH agonist therapy (leuprolide, for example) will have profoundly suppressed LH as a sign the medication is working. Serum LH below 1 IU/L confirms adequate GnRH agonist suppression.

Pregnancy, Lactation, and LH: What You Need to Know

LH is suppressed during pregnancy. Once implantation occurs, rising hCG takes over LH receptor signaling to maintain the corpus luteum through the first trimester, and LH itself falls to very low levels. Testing LH during pregnancy is not clinically useful for monitoring the pregnancy.

During lactation, prolactin suppresses GnRH pulsatility, which keeps LH low and ovulation suppressed. This is the mechanism behind lactational amenorrhea. The lactational amenorrhea method (LAM) is approximately 98% effective as contraception in the first six months postpartum when a woman is exclusively breastfeeding and has not yet had a period, precisely because LH surges are blunted by hyperprolactinemia. However, the first ovulation after delivery can occur before the first postpartum period, meaning a woman can conceive before she ever sees a period return. LH testing at home will not reliably predict this.

LH testing has no role in monitoring pregnancy or lactation directly. It is a tool for the phases before and after these states.

How to Time Your LH Draw for Accurate Results

Getting an LH result that means something requires knowing when to draw it.

For Cycle-Tracking or PCOS Evaluation

Draw on cycle day 2, 3, or 4. Day 1 is the first day of full flow. A same-day FSH and estradiol adds essential context. Fasting is preferred (not always required, but avoids food-related LH pulse variation). Morning is ideal, as LH has a mild diurnal peak in the early morning.

For Ovulation Confirmation

Serum LH drawn at peak (which you may not catch without daily draws) will show the surge value of 21.9-56.6 IU/L. Practically, urine LH strips are a better tool for ovulation detection at home because they can be done twice daily.

For Perimenopause or Postmenopause Evaluation

Any morning draw without a recent period works. Pair with FSH and estradiol. If you are on hormone therapy, the test is less interpretable unless you are specifically checking for pituitary disease.

What to Tell Your Clinician Before the Draw

Tell your clinician the first day of your last period, any hormonal medications (birth control pills, patches, rings, progestogen IUDs, injectable progestins, GnRH analogs all suppress LH), and any supplements with phytoestrogens or soy isoflavones at high doses that may modestly affect the axis.

Who Should Have LH Measured

LH testing is appropriate in specific clinical situations, not as a general wellness screen. The ASRM recommends LH as part of a baseline fertility evaluation when cycles are irregular or when ovulation induction is being considered.

You are a good candidate for LH testing if you:

• Have irregular or absent cycles at any reproductive age
• Are trying to conceive and cycles are irregular or infrequent
• Are under 40 with cycle changes, hot flashes, or other signs of early ovarian decline
• Are being evaluated for suspected PCOS, hypothalamic amenorrhea, or hypopituitarism
• Are starting or monitoring GnRH agonist therapy for endometriosis, fibroids, or another indication
• Are your clinician is distinguishing primary from secondary hypogonadism

You do not need LH testing if:

• You have regular 24-to-35-day cycles, are not trying to conceive, and have no symptoms
• You are already confirmed postmenopausal with no new symptoms
• You want to "check your fertility" (AMH and antral follicle count are better tools for ovarian reserve)

Optimal LH: Is There a Target Beyond "Normal"?

The word "optimal" is used loosely in functional medicine circles. For most women, the clinical goal is an LH that reflects normal HPO function for their life stage, not a specific number within the lab range. There is no longevity evidence that an LH of 5 IU/L is better than 9 IU/L in a 32-year-old with regular cycles.

Where "optimal" becomes clinically meaningful:

• In women undergoing ovulation induction, the goal is a follicular-phase LH below 10 IU/L before trigger to avoid premature luteinization.
• In women on GnRH agonist therapy, suppression to below 1 IU/L confirms therapeutic efficacy.
• In postmenopausal women on hormone therapy, the clinical goal is symptom control and bone protection, not a specific LH target.

Women have been under-represented in HPO axis pharmacology trials, meaning much of what clinicians apply about "optimal" LH during ovulation induction is extrapolated from trial populations that skewed toward IVF patients with identifiable diagnoses rather than the broader population of women with subfertility. This evidence gap is real. Interpret "optimal" claims with appropriate skepticism unless they are tied to a specific clinical endpoint.